SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Up 2.8% – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) shares traded up 2.8% on Friday . The stock traded as high as $4.75 and last traded at $4.73. 45,371 shares traded hands during trading, a decline of 38% from the average session volume of 73,308 shares. The stock had previously closed at $4.60.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SOPH. Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. Finally, BTIG Research raised their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS Stock Up 2.8%

The company has a fifty day simple moving average of $4.59 and a 200-day simple moving average of $3.88. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78. The firm has a market cap of $319.65 million, a P/E ratio of -10.28 and a beta of 1.10.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). The company had revenue of $19.46 million during the quarter, compared to the consensus estimate of $18.13 million. SOPHiA GENETICS had a negative return on equity of 37.75% and a negative net margin of 41.13%. On average, equities analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the period. Savvy Advisors Inc. bought a new stake in SOPHiA GENETICS during the third quarter valued at about $48,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the third quarter valued at about $49,000. Silverberg Bernstein Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 31.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company’s stock valued at $142,000 after acquiring an additional 11,040 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of SOPHiA GENETICS in the third quarter worth about $59,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.